Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

2017 NCCN Annual Conference

Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer C...

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen ...

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cance...

Issues in Oncology

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Paul M. Cinciripini, PhD, of The University...

Bladder Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elizabeth R. Plimack, MD, of Fox Chase Canc...

Jul

Today In Oncology

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Related Videos

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Continuous Coverage of COVID-19

Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma

GI-Related Patient-Reported Outcomes in Those Receiving Chemoradiation for Anal Cancer

Risk of Breast Cancer Recurrence Serum Detection of Nonadherence to Adjuvant Tamoxifen

Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Pancreatic Cancer Across Age Groups Additional Analysis of the POLO Trial